Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardian Pharmacy Services (GRDN) EBITDA (2023 - 2025)

Guardian Pharmacy Services' EBITDA history spans 3 years, with the latest figure at $30.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 83.6% year-over-year to $30.8 million; the TTM value through Dec 2025 reached $72.7 million, up 215.55%, while the annual FY2025 figure was $72.7 million, 215.55% up from the prior year.
  • EBITDA for Q4 2025 was $30.8 million at Guardian Pharmacy Services, up from $16.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $30.8 million in Q4 2025 and bottomed at -$104.6 million in Q3 2024.
  • The 3-year median for EBITDA is $15.5 million (2023), against an average of $2.8 million.
  • The largest YoY upside for EBITDA was 115.63% in 2025 against a maximum downside of 26.02% in 2025.
  • A 3-year view of EBITDA shows it stood at $15.5 million in 2023, then rose by 7.93% to $16.8 million in 2024, then soared by 83.6% to $30.8 million in 2025.
  • Per Business Quant, the three most recent readings for GRDN's EBITDA are $30.8 million (Q4 2025), $16.4 million (Q3 2025), and $12.6 million (Q2 2025).